新日本科学（snbl）は1957年に創業した、わが国初の医薬品開発受託研究機関（cro）です。

SNBL provides high-quality services and tailored solutions to your needs with a proven technical capability backed by more than 60 years of abundant experience and achievements. Learn More

株式会社新日本科学 の「会社概要 」ページです。

2022年11月14日 · SNBL's NDS, the μco™ System, consists of two technologies: a safe and muco-adhesive nasal drug carrier technology (in powder form), and a non-invasive and easy …

SNBL has developed a proprietary nasal drug delivery technology, μco™ System, consisting of a powder carrier technology (μco™ Carrier) designed for increased drug absorption through its …

SNBL 1,341 (as of March 31, 2024) Entire group 2,762 members (including equity-method affiliates, etc.) Main Business Activities: Contract Research Organization (CRO) Business …

We introduce the history of our company since its founding in 1957.

Established in 2024, SNBL Global Gateway (SGG) is a joint venture between SNBL—Japan’s largest and most experienced nonclinical CRO—and SBI Group. SGG was created to foster …

The mission of SNBL Group is to free patients from suffering by supporting drug development and improving medical technology. The nonclinical research division of SNBL is Japan’s largest and...

The nonclinical research division of SNBL is Japan’s largest and oldest nonclinical CRO. For over 65 years, we have balanced speed with superior quality, carrying out studies efficiently,...